Results 51 to 60 of about 5,866 (194)

A randomized phase II trial of gemcitabine, nab‐paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer

Cancer, Volume 132, Issue 6, 15 March 2026.
ABSTRACT Background A randomized phase II screening trial of gemcitabine, nab‐paclitaxel, and cisplatin with a medically supervised ketogenic diet (MSKD) versus usual diet (non‐MSKD) was conducted in patients with treatment‐naive metastatic pancreatic ductal adenocarcinoma (PDAC).
Gayle S. Jameson, Denise J. Roe, Erkut Borazanci, Diana L. Hanna, Caroline G. P. Roberts, Meredith S. Pelster, Richard C. Frank, Angela T. Alistar, Alan M. Miller, J. Erin Wiedmeier‐Nutor, Sandra D. Algaze, Alison R. Zoller, Sarah J. Hallberg, Betsy C. Wertheim, Keehoon Lee, Derek Cridebring, Joshua D. Rabinowitz, Stephen Gately, Jennifer Keppler, Sunil Sharma, Daniel D. Von Hoff, Drew W. Rasco   +21 more
wiley   +1 more source

Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis

BMC Cancer, 2011
Background Febrile neutropenia (FN) occurs following myelosuppressive chemotherapy and is associated with morbidity, mortality, costs, and chemotherapy reductions and delays. Granulocyte colony-stimulating factors (G-CSFs) stimulate neutrophil production
Stevenson Matt D, Whyte Sophie, Madan Jason, Cooper Katy L, Akehurst Ron L   +4 more
doaj   +1 more source

Society for Maternal‐Fetal Medicine Consult Series #76: Cancer in pregnancy

Pregnancy, Volume 2, Issue 2, March 2026.
Abstract Approximately one in 1000 pregnancies is complicated by the diagnosis of cancer each year, and the incidence of cancer among reproductive‐age individuals is increasing. Management of a pregnant person with cancer can be complex and warrants a multidisciplinary approach to care.
Society for Maternal‐Fetal Medicine (SMFM), Moti Gulersen, Clarissa Bonanno, Justin S. Brandt, Stephanie Pierce, Elyce H. Cardonick, SMFM Publications Committee   +6 more
wiley   +1 more source

Pegfilgrastim [PDF]

Reactions Weekly, 2020
  +7 more sources

Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)

Frontiers in Oncology, 2023
IntroductionPegylated granulocyte colony-stimulating factor (G-CSF) has been widely used for preventing febrile neutropenia in various types of cancer treatment. In the present study, we prospectively evaluated the safety and efficacy of pegfilgrastim as
Ga-Young Song, Je-Jung Lee, Joon Ho Moon, Dajung Kim, Min Kyoung Kim, Hyo Jung Kim, Yeung-Chul Mun, Won-Sik Lee, Young Rok Do, Jae Hoon Lee, Sung-Hoon Jung, Jin Seok Kim   +11 more
doaj   +1 more source

Enhancing Severe Neutropenia Prediction: PKPD‐Informed Labeling for Machine Learning Models Trained on Real‐World Data

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 427-436, February 2026.
Accurately labeling outcomes in real‐world data for machine learning is challenging due to data sparsity and imbalances. This study developed and evaluated a pharmacokinetic–pharmacodynamic (PKPD)‐informed labeling strategy to enhance the risk prediction of docetaxel‐induced neutropenia.
Conor J O’Hanlon, Jonas Denck, Elif Ozkirimli, Stefanie Bendels, Candice Jamois, Clarisse Chavanne, Dirk Fey, Kimmo Porkka, Oscar Brück, Ken Wang   +9 more
wiley   +1 more source

Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in patients with non-Hodgkin's lymphoma in the United Kingdom (UK) [PDF]

Introduction: We report a cost-effectiveness evaluation of granulocyte colony-stimulating factors (G-CSFs) for prevention of febrile neutropenia (FN) following chemotherapy for non-Hodgkin’s lymphoma (NHL) in the United Kingdom (UK).
Akehurst, R., Cooper, K.L., Stevenson, M.D., Whyte, S.   +3 more
core   +3 more sources

Efficacy of Early Switching From Docetaxel to Cabazitaxel in Castration‐Resistant Prostate Cancer

The Prostate, Volume 86, Issue 3, Page 297-306, February 15, 2026.
ABSTRACT Background Cabazitaxel is a taxane agent associated with fewer symptomatic adverse events than docetaxel in treating castration‐resistant prostate cancer (CRPC), yet it is typically reserved for post‐docetaxel failure. This study assessed whether early switching from docetaxel to cabazitaxel could improve clinical outcomes.
Taketo Kawai, Kazuki Maki, Satoru Taguchi, Yoichi Fujii, Takehiro Tanaka, Jimpei Miyakawa, Jun Kamei, Shigenori Kakutani, Aya Niimi, Daisuke Yamada, Yuta Yamada, Tappei Takada, Tohru Nakagawa, Haruki Kume   +13 more
wiley   +1 more source

Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer

Frontiers in Pharmacology, 2017
Background: Lipegfilgrastim (Lonquex®) has demonstrated to be non-inferior to pegfilgrastim (Neulasta®) in reducing the duration of severe neutropenia (SN) in patients with stage II−IV breast cancer.
Esse I. H. Akpo, Irshaad R. Jansen, Edith Maes, Steven Simoens   +3 more
doaj   +1 more source

Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer

Cancer Reports, 2023
Background Pegfilgrastim is recommended in docetaxel plus ramucirumab (DTX + RAM) therapy for recurrent nonsmall cell lung cancer (NSCLC) because of the associated frequency of febrile neutropenia (FN).
Kosuke Hamai, Shinya Miyaka, Shinpei Tada, Suguru Fujita, Tetsu Hirakawa, Mirai Matsumura, Sayaka Ueno, Takuya Tanimoto, Nobuhisa Ishikawa   +8 more
doaj   +1 more source